Alternatively spliced tissue factor pathway inhibitor: Functional implications

Frontiers in Bioscience - Scholar

Volumn 3 S, Issue 4, 2011, Pages 1457-1462

  Mast, Alan E ^a,b  

^a BLOOD RESEARCH INSTITUTE   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Alternative splicing; Factor VIIa; Factor Xa; Review; Tissue factor pathway inhibitor

Indexed keywords

CAVEOLIN 1; CYSTEINE; GLYCOSAMINOGLYCAN; HEPARIN; PROTEIN S; TISSUE FACTOR PATHWAY INHIBITOR; BLOOD CLOTTING FACTOR 10A; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR;

3' UNTRANSLATED REGION; ALTERNATIVE RNA SPLICING; AMINO ACID SEQUENCE; ANTIBACTERIAL ACTIVITY; ANTICOAGULATION; ARTICLE; BINDING SITE; BLOOD CLOTTING; CARBOXY TERMINAL SEQUENCE; CAVEOLA; CELL SURFACE; EXON; GENETIC CONSERVATION; HUMAN; NONHUMAN; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RNA TRANSLATION; STOP CODON; THROMBOCYTE; ANIMAL; CHEMICAL STRUCTURE; COMPARATIVE STUDY; DRUG ANTAGONISM; GENETICS; METABOLISM; MOLECULAR EVOLUTION; MOLECULAR GENETICS; MOUSE; REVIEW; SPECIES DIFFERENCE;

ALTERNATIVE SPLICING; AMINO ACID SEQUENCE; ANIMALS; EVOLUTION, MOLECULAR; FACTOR XA; HUMANS; LIPOPROTEINS; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; SPECIES SPECIFICITY;

EID: 80053100269     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: 10.2741/s236     Document Type: Article

References (30)

1. Bajaj MS, Kuppuswamy MN, Saito H, Spitzer SG, Bajaj SP. Cultured Normal Human Hepatocytes do not Synthesize Lipoprotein-Associated Coagulation Inhibitor: Evidence that Endothelium is the Principal Site of Its Synthesis. PNAS 87, 8869-8873 (1990)
2. Novotny WF, Girard TJ, Miletich JP, Broze GJ, Jr. Platelets secrete a coagulation inhibitor functionally and antigenically similar to the lipoprotein associated coagulation inhibitor. Blood 72, 2020-2025 (1988)
3. Maroney SA, Haberichter SL, Friese P, Collins ML, Ferrel JP, Dale GL, Mast AE. Active tissue factor pathway inhibitor is expressed on the surface of coated platelets. Blood 109, 1931-1937 (2007)
4. Novotny WF, Girard TJ, Miletich JP, Broze GJ, Jr. Purification and characterization of the lipoprotein-associated coagulation inhibitor from human plasma. J Biol Chem 264, 18832-71883 (1989)
5. Huang ZF, Higuchi D, Lasky N, Broze GJ, Jr. Tissue factor pathway inhibitor gene disruption produces intrauterine lethality in mice. Blood 90, 944-951 (1997)
6. Pedersen B, Holscher T, Sato Y, Pawlinski R, Mackman N. A balance between tissue factor and tissue factor pathway inhibitor is required for embryonic development and hemostasis in adult mice. Blood 105, 2777-2782 (2005)
7. Chan JC, Carmeliet P, Moons L, Rosen ED, Huang ZF, Broze GJ, Jr., Collen D, Castellino FJ. Factor VII deficiency rescues the intrauterine lethality in mice associated with a tissue factor pathway inhibitor deficit. J Clin Invest 103, 475-482 (1999)
8. Wun TC, Kretzmer KK, Girard TJ, Miletich JP, Broze GJ, Jr. Cloning and characterization of a cDNA coding for the lipoprotein- associated coagulation inhibitor shows that it consists of three tandem Kunitz-type inhibitory domains. J Biol Chem 263, 6001-6004 (1988)
9. Girard TJ, Warren LA, Novotny WF, Likert KM, Brown SG, Miletich JP, Broze GJ, Jr. Functional significance of the Kunitz-type inhibitory domains of lipoprotein-associated coagulation inhibitor. Nature 338, 518-520 (1989)
10. Chang JY, Monroe DM, Oliver JA, Roberts HR. TFPIbeta, a second product from the mouse tissue factor pathway inhibitor TFPI) gene. Thromb Haemost 81, 45-49 (1999)
11. Zhang J, Piro O, Lu L, Broze GJ, Jr. Glycosyl phosphatidylinositol anchorage of tissue factor pathway inhibitor. Circulation 2003 108, 623-627 (2003)
12. Maroney SA, Ferrel JP, Collins ML, Mast AE. TFPIgamma is an active alternatively spliced form of TFPI present in mice but not in humans. J Thromb Haemost 6, 1344-1351 (2008)
13. Maroney SA, Ferrel JP, Pan S, White TA, Simari RD, McVey JH, Mast AE. Temporal expression of alternatively spliced forms of tissue factor pathway inhibitor in mice. J Thromb Haemost 7, 1106-1113 (2009)
14. Maroney SA, Ellery PE, Mast AE. Alternatively spliced isoforms of tissue factor pathway inhibitor. Thromb Res 125 Suppl 1, S52-S56 (2010)
15. Piro O, Broze GJ, Jr. Role for the Kunitz-3 Domain of Tissue Factor Pathway Inhibitor-{alpha} in Cell Surface Binding. Circulation 110, 3567-3572 (2004)
16. Sevinsky JR, Rao LV, Ruf W. Ligand-induced proteasereceptor translocation into caveolae: a mechanism for regulating cell surface proteolysis of the tissue factordependent coagulation pathway. J Cell Biol 133, 293-304 (1996)
17. Mast AE, Acharya N, Malecha MJ, Hall CL, Dietzen DJ. Characterization of the association of tissue factor pathway inhibitor with human placenta. Arterioscler Thromb Vasc Biol 22, 2099-2104 (2002)
18. Lupu C, Hu X, Lupu F. Caveolin-1 Enhances Tissue Factor Pathway Inhibitor Exposure and Function on the Cell Surface. J Biol Chem 280, 22308-22317 (2005)
19. Sandset PM, Abildgaard U, Larsen ML. Heparin induces release of extrinsic coagulation pathway inhibitor EPI). Thromb Res 50, 803-813 (1988)
20. Novotny WF, Palmier M, Wun TC, Broze GJ, Jr., Miletich JP. Purification and properties of heparinreleasable lipoprotein- associated coagulation inhibitor. Blood 78, 394-400 (1991)
21. Cunningham AC, Hasty KA, Enghild JJ, Mast AE. Structural and functional characterization of tissue factor pathway inhibitor following degradation by matrix metalloproteinase-8. Biochem J 367, 451-458 (2002)
22. Wesselschmidt R, Likert K, Girard T, Wun TC, Broze GJ, Jr. Tissue factor pathway inhibitor: the carboxyterminus is required for optimal inhibition of factor Xa. Blood 79, 2004-2010 (1992)
23. Lockett JM, Mast AE. Contribution of regions distal to glycine-160 to the anticoagulant activity of tissue factor pathway inhibitor. Biochemistry 41, 4989-4997 (2002)
24. Hamamoto T, Yamamoto M, Nordfang O, Petersen JG, Foster DC, Kisiel W. Inhibitory properties of full-length and truncated recombinant tissue factor pathway inhibitor TFPI). Evidence that the third Kunitz-type domain of TFPI is not essential for the inhibition of factor VIIa- tissue factor complexes on cell surfaces. J Biol Chem 268, 8704-8710 (1993)
25. Hackeng TM, Sere KM, Tans G, Rosing J. Protein S stimulates inhibition of the tissue factor pathway by tissue factor pathway inhibitor. Proc Natl Acad Sci U S A 103, 3106-3111 (2006)
26. Ndonwi M, Tuley EA, Broze GJ, Jr. The Kunitz-3 domain of TFPI-alpha is required for protein S-dependent enhancement of factor Xa inhibition. Blood 2010 116, 1344-1351 (2010)
27. Ndonwi M, Broze G, Jr. Protein S enhances the tissue factor pathway inhibitor inhibition of factor Xa but not its inhibition of factor VIIa-tissue factor. J Thromb Haemost 6, 1044-1046 (2008)
28. Hembrough TA, Ruiz JF, Swerdlow BM, Swartz GM, Hammers HJ, Zhang L, Plum SM, Williams MS, Strickland DK, Pribluda VS. Identification and characterization of a very low density lipoprotein receptor-binding peptide from tissue factor pathway inhibitor that has antitumor and antiangiogenic activity. Blood 103, 374-3380 (2004)
29. Schirm S, Liu X, Jennings LL, Jedrzejewski P, Dai Y, Hardy S. Fragmented tissue factor pathway inhibitor TFPI) and TFPI C-terminal peptides eliminate serum-resistant Escherichia coli from blood cultures. J Infect Dis 199, 1807-1815 (2009)
30. Papareddy P, Kalle M, Kasetty G, Morgelin M, Rydengard V, Albiger B, Lundqvist K, Malmsten M, Schmidtchen A. C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. J Biol Chem 285, 28387-28398 (2010)